Surrogate insulin resistance indices track diabetic retinopathy risk in type 2 diabetes
Among patients with type 2 diabetes, routine metabolic markers may carry more information than many clinics currently use. In a matched case-control study of 1,230 people, several surrogate insulin resistance indices were nonlinearly associated with diabetic retinopathy, and those same measures also showed useful discrimination for identifying eye disease from routine clinical data.
The signal was not uniform across indices. VAI, LAP, METS-IR, and the TG/HDL-C ratio each tracked with retinopathy presence, while TyG did not reach a significant association in this analysis. That uneven pattern matters because the indices are all intended to approximate insulin resistance, yet they do not capture the same metabolic terrain. Some weight central adiposity and lipid handling more heavily than others, and those components may be closer to the vascular injury that accumulates in the retina.
A nonlinear metabolic signal emerged across the cohort
The study enrolled 615 patients with retinopathy and 615 without, a design that allowed direct comparison between cases and matched controls. Restricted cubic spline modeling showed significant nonlinear relationships between all evaluated indices and diabetic retinopathy, with higher values generally linked to greater odds of disease. In practical terms, the relationship did not behave like a simple straight line; risk rose in a curved fashion, suggesting that metabolic burden may begin to accelerate after certain thresholds are crossed.
One sentence captures the pattern plainly: higher surrogate insulin resistance values were consistently associated with worse retinal disease.
Among the tested measures, VAI showed the strongest association. Compared with the lowest tertile, the second tertile carried an odds ratio of 1.69, with a 95% confidence interval of 1.24 to 2.30, and the third tertile carried an odds ratio of 2.40, with a 95% confidence interval of 1.72 to 3.35. Those graded increases suggest that the most adiposity-sensitive index in the set may be especially informative for retinal microvascular injury. The result also points to a broader biologic theme: insulin resistance, dyslipidemia, and visceral fat dysfunction tend to travel together, and the retina may be one of the first vascular beds to reveal the cost.
Why insulin resistance could translate into retinal injury
The pathophysiologic logic is credible even before any screening algorithm is built. Insulin resistance promotes atherogenic lipid patterns, endothelial dysfunction, oxidative stress, and chronic low-grade inflammation. In the retina, where capillary networks are delicate and metabolically active, those pressures can disrupt microcirculation and promote the vascular leakage, ischemia, and tissue remodeling that define retinopathy. An index such as LAP, which reflects central adiposity and triglyceride burden, may therefore outperform a purely glycemic surrogate if the retinal lesion is being driven by a broader cardiometabolic disturbance rather than glucose alone.
The absence of a significant association for TyG is useful, not discouraging. It suggests that not every surrogate marker of insulin resistance behaves identically in eye disease, and that a composite reflecting body fat distribution and lipid flux may be more sensitive to retinal risk than fasting triglyceride and glucose alone. For clinicians, this creates a more selective message: when the question is retinal microvascular injury, the most informative metabolic proxy may not be the simplest one.
Diagnostic performance stayed in a clinically usable range
Diagnostic utility was examined with receiver operating characteristic analysis, and all of the indices reached an area under the curve of at least 0.758. LAP produced the highest AUC at 0.780, with a 95% confidence interval of 0.722 to 0.837. That is not a stand-alone diagnostic threshold for retinopathy, and no clinician should treat any one surrogate index as a substitute for retinal examination. It does mean, however, that routinely available laboratory and anthropometric data could help flag patients whose retinal evaluation should be prioritized.
This is the bedside implication. In a busy diabetes clinic, risk stratification often depends on whether a patient is already known to be high risk through duration of diabetes, glycemic control, blood pressure, or visible retinal symptoms. Surrogate insulin resistance indices could add another layer without requiring specialized testing. Because they can be calculated from routinely collected measurements, they may be easier to incorporate into electronic risk tools than more resource-intensive biomarkers.
What the matched design can and cannot prove
The cross-sectional, matched case-control structure supports association, not causation. It cannot establish whether insulin resistance precedes retinopathy progression in a temporal sense, or whether retinopathy itself influences the metabolic profile being measured. The design also does not answer whether treating insulin resistance directly would reduce retinal complications. What it does provide is a tightly matched snapshot showing that metabolic surrogates and retinal disease cluster together in a way that is not random.
The statistical approach was broad, combining restricted cubic splines, generalized linear mixed-effects models, threshold effect analysis, and ROC analysis. That analytical range strengthens confidence that the observed relationships were not a single-model artifact. Still, the study does not supply a universal cut-point for screening, nor does it show how these indices would perform against established ophthalmic assessment pathways in routine practice. The real-world question is therefore narrower: can an inexpensive metabolic score help identify which patients with type 2 diabetes deserve faster eye evaluation?
For now, the answer is provisional but clinically relevant. In this cohort, surrogate insulin resistance indices were linked to diabetic retinopathy in nonlinear fashion, and several performed well enough to merit further study as practical screening aids. The strongest signal came from VAI and LAP, while TyG was less convincing. Future work will need to test whether these indices improve prediction beyond standard diabetes care variables and whether they can prospectively identify patients at risk before retinal damage becomes established.